Seattle Genetics Inc. (SGEN)

71.80
NASDAQ : Health Technology
Prev Close 73.72
Day Low/High 70.71 / 74.15
52 Wk Low/High 47.75 / 84.37
Avg Volume 780.60K
Exchange NASDAQ
Shares Outstanding 158.79M
Market Cap 11.71B
EPS -0.90
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Seattle Genetics And Takeda Announce Positive Results From Phase 3 ECHELON-2 Clinical Trial Evaluating ADCETRIS® (Brentuximab Vedotin) In Frontline CD30-Expressing Peripheral T-Cell Lymphoma

Seattle Genetics And Takeda Announce Positive Results From Phase 3 ECHELON-2 Clinical Trial Evaluating ADCETRIS® (Brentuximab Vedotin) In Frontline CD30-Expressing Peripheral T-Cell Lymphoma

Seattle Genetics, Inc. (Nasdaq:SGEN) and Takeda Pharmaceutical Company Limited ( TSE:4502) announced today that the phase 3 ECHELON-2 clinical trial met its primary endpoint.

Seattle Genetics Announces ADCETRIS® (Brentuximab Vedotin) Approval In Japan For Frontline Hodgkin Lymphoma

Seattle Genetics Announces ADCETRIS® (Brentuximab Vedotin) Approval In Japan For Frontline Hodgkin Lymphoma

Seattle Genetics, Inc. (Nasdaq: SGEN) today announced that its collaborator, Takeda Pharmaceutical Company Limited (Takeda), has received approval from the Japanese Ministry of Health, Labour and Welfare for ADCETRIS (brentuximab vedotin) in combination...

Seattle Genetics To Present At The Morgan Stanley Global Healthcare Conference

Seattle Genetics To Present At The Morgan Stanley Global Healthcare Conference

Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that management will present at the Morgan Stanley Global Healthcare Conference on Thursday, September 13, 2018 at 2:05 p.

Seattle Genetics Reports Second Quarter 2018 Financial Results

Seattle Genetics Reports Second Quarter 2018 Financial Results

Seattle Genetics, Inc. (Nasdaq:SGEN) today reported financial results for the second quarter and six months ended June 30, 2018.

Seattle Genetics Announces First Patient Dosed In Phase 2 InnovaTV 207 Trial Evaluating Tisotumab Vedotin In Multiple Solid Tumors

Seattle Genetics Announces First Patient Dosed In Phase 2 InnovaTV 207 Trial Evaluating Tisotumab Vedotin In Multiple Solid Tumors

Seattle Genetics, Inc. (Nasdaq:SGEN) today announced dosing of the first patient in the phase 2 innovaTV 207 clinical trial evaluating the activity, safety and tolerability of tisotumab vedotin as monotherapy in selected solid tumors with high Tissue...

Cisco Systems, Herbalife, Under Armour: 'Mad Money' Lightning Round

Cisco Systems, Herbalife, Under Armour: 'Mad Money' Lightning Round

Jim Cramer takes a closer look at Cisco Systems, Herbalife, Under Armour, Axon Enterprise, Seattle Genetics, Roku, Procter & Gamble, Bank of Nova Scotia.

Tariffs Fueling Rotation: Cramer's 'Mad Money' Recap (Wednesday 7/11/18)

Tariffs Fueling Rotation: Cramer's 'Mad Money' Recap (Wednesday 7/11/18)

Jim Cramer says tariff news doesn't really rattle the markets, it moves money from one sector to another. Here's his strategy for navigating this volatility.

Seattle Genetics Announces Publication Of Results From Two Tucatinib Phase 1b Clinical Trials In HER2-Positive Metastatic Breast Cancer

Seattle Genetics Announces Publication Of Results From Two Tucatinib Phase 1b Clinical Trials In HER2-Positive Metastatic Breast Cancer

Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that results of a phase 1b clinical trial of tucatinib in combination with standard of care agents for the treatment of patients with advanced HER2-positive (HER2+) metastatic breast cancer were...

Seattle Genetics And Astellas Announce Progress In Enfortumab Vedotin Urothelial Cancer Clinical Development Program

Seattle Genetics And Astellas Announce Progress In Enfortumab Vedotin Urothelial Cancer Clinical Development Program

-Enrollment of EV-201 Pivotal Trial Cohort Designed to Support Potential Expedited Registration Pathway in the U.S. Completed-

Seattle Genetics And Astellas Announce Progress In Enfortumab Vedotin Urothelial Cancer Clinical Development Program

Seattle Genetics And Astellas Announce Progress In Enfortumab Vedotin Urothelial Cancer Clinical Development Program

Seattle Genetics, Inc. (Nasdaq:SGEN) and Astellas Pharma Inc.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: APOG, LNN, LTC, MLAB, NKE, SGEN Downgrades: DIT, GMS, PDVW, WUBA Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Seattle Genetics To Host Conference Call And Webcast Discussion Of Second Quarter Financial Results On July 26, 2018

Seattle Genetics To Host Conference Call And Webcast Discussion Of Second Quarter Financial Results On July 26, 2018

Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its second quarter financial results on Thursday, July 26, 2018 after the close of financial markets.

Seattle Genetics Announces First Patient Dosed In Phase 2 Trial Of Tisotumab Vedotin For Women With Recurrent Or Metastatic Cervical Cancer

Seattle Genetics Announces First Patient Dosed In Phase 2 Trial Of Tisotumab Vedotin For Women With Recurrent Or Metastatic Cervical Cancer

Seattle Genetics, Inc. (Nasdaq:SGEN) today announced dosing of the first patient in the phase 2 innovaTV 204 clinical trial evaluating the efficacy, safety and tolerability of tisotumab vedotin as monotherapy for patients with recurrent and/or metastatic...

Seattle Genetics To Present At The Goldman Sachs 39th Annual Global Healthcare Conference

Seattle Genetics To Present At The Goldman Sachs 39th Annual Global Healthcare Conference

Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that management will present at the Goldman Sachs 39 th Annual Global Healthcare Conference on Wednesday, June 13, 2018 at 1:20 p.

Seattle Genetics Highlights Additional Analyses From Phase 3 ECHELON-1 Clinical Trial Of ADCETRIS® (Brentuximab Vedotin) In Newly Diagnosed Advanced Hodgkin Lymphoma At 2018 ASCO Annual Meeting

Seattle Genetics Highlights Additional Analyses From Phase 3 ECHELON-1 Clinical Trial Of ADCETRIS® (Brentuximab Vedotin) In Newly Diagnosed Advanced Hodgkin Lymphoma At 2018 ASCO Annual Meeting

Seattle Genetics, Inc. (Nasdaq:SGEN) today highlighted data from the phase 3 ECHELON-1 clinical trial evaluating ADCETRIS (brentuximab vedotin) in combination with chemotherapy in newly diagnosed stage III or IV classical Hodgkin lymphoma (HL) at the 2018...

Astellas And Seattle Genetics Present At ASCO 2018 On Enfortumab Vedotin In Patients With Locally Advanced Or Metastatic Urothelial Cancer Previously Treated With Checkpoint Inhibitor Therapy

Astellas And Seattle Genetics Present At ASCO 2018 On Enfortumab Vedotin In Patients With Locally Advanced Or Metastatic Urothelial Cancer Previously Treated With Checkpoint Inhibitor Therapy

-Updated Data from Phase 1 EV-101 Study Highlighted in ASCO 2018 Oral Presentation Support Rapid Development Program and Ongoing Pivotal Study-

Seattle Genetics Appoints Roger D. Dansey, M.D., Chief Medical Officer

Seattle Genetics Appoints Roger D. Dansey, M.D., Chief Medical Officer

Seattle Genetics, Inc. (Nasdaq: SGEN) today announced the appointment of Roger D.

Seattle Genetics Announces Data Presentations At 2018 ASCO Annual Meeting

Seattle Genetics Announces Data Presentations At 2018 ASCO Annual Meeting

Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that multiple abstracts from its robust clinical development portfolio will be presented at the upcoming 2018 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois, from June...

Seattle Genetics To Present At The Bank Of America Merrill Lynch Health Care Conference 2018

Seattle Genetics To Present At The Bank Of America Merrill Lynch Health Care Conference 2018

Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that management will present at the Bank of America Merrill Lynch Health Care Conference 2018 on Tuesday, May 15, 2018 at 5:00 p.

Seattle Genetics Reports First Quarter 2018 Financial Results

Seattle Genetics Reports First Quarter 2018 Financial Results

Seattle Genetics, Inc. (Nasdaq: SGEN) today reported financial results for the first quarter ended March 31, 2018.

Seattle Genetics To Host Conference Call And Webcast Discussion Of First Quarter Financial Results On April 26, 2018

Seattle Genetics To Host Conference Call And Webcast Discussion Of First Quarter Financial Results On April 26, 2018

Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its first quarter financial results on Thursday, April 26, 2018 after the close of financial markets.

Http://www.astellas.com/en

Http://www.astellas.com/en

Seattle Genetics, Inc. (NASDAQ: SGEN) and Astellas Pharma Inc.

Seattle Genetics Appoints Dr. Alpna Seth To Board Of Directors

Seattle Genetics Appoints Dr. Alpna Seth To Board Of Directors

Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that Alpna Seth, Ph.

Seattle Genetics To Present At The Barclays Global Healthcare Conference 2018

Seattle Genetics To Present At The Barclays Global Healthcare Conference 2018

Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that management will present at the Barclays Global Healthcare Conference 2018 on Wednesday, March 14, 2018 at 10:45 a.

Seattle Genetics Completes Acquisition Of Cascadian Therapeutics

Seattle Genetics Completes Acquisition Of Cascadian Therapeutics

Seattle Genetics, Inc. (Nasdaq:SGEN) today announced it has completed its previously announced acquisition of Cascadian Therapeutics, Inc.

Seattle Genetics Completes Tender Offer For All Shares Of Cascadian Therapeutics

Seattle Genetics Completes Tender Offer For All Shares Of Cascadian Therapeutics

Seattle Genetics, Inc. (Nasdaq:SGEN) today announced the expiration of the tender offer (the "Offer") by a wholly owned subsidiary, "Merger Sub", for all of the shares of common stock of Cascadian Therapeutics, Inc.

TheStreet Quant Rating: C (Hold)